ArticleLab on a chip2020
A modular microarray imaging system for highly specific COVID-19 antibody testing.
Article in Lab on a chip, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- Molecular Mechanisms of Mangiferin on Neuroinflammation for Treating Major Depressive Disorder Based on Network Pharmacology and Bioinformatics Analysis.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Article
- Correlative humoral and cellular immunity to genetically attenuated malaria parasites in humans.iScience · 2025Article
- Concordance of maternal and cord blood SARS-COV-2 immunoglobulin seropositivity after COVID-19 infection or vaccination in pregnancy.Journal of neonatal-perinatal medicine · 2025Article
- Development and evaluation of a lyophilization protocol for colorimetric RT-LAMP diagnostic assay for COVID-19.Scientific reports · 2024Article
- Advancing Point-of-Care Diagnosis: Digitalizing Combinatorial Biomarker Signals for Lupus Nephritis.Biosensors · 2024Article
- Numerical and Experimental Investigation on a "Tai Chi"-Shaped Planar Passive Micromixer.Micromachines · 2023Article
- Coronavirus: a comparative analysis of detection technologies in the wake of emerging variants.Infection · 2023Review
- Article
- Peptide Microarrays for Flavivirus Diagnosis.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Rapid and quantitative detection of multiple antibodies against SARS-CoV-2 mutant proteins by photo-immobilized microarray.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2022Article
- A Protein Microarray-Based Respiratory Viral Antigen Testing Platform for COVID-19 Surveillance.Biomedicines · 2022Article
- Rapid Antigen Diagnostics as Frontline Testing in the COVID-19 Pandemic.Small science · 2022Article
- Smartphone-Based Quantitative Analysis of Protein Array Signals for Biomarker Detection in Lupus.Chemosensors (Basel, Switzerland) · 2022Article
- Antibody profiles in COVID-19 convalescent plasma prepared with amotosalen/UVA pathogen reduction treatment.Transfusion · 2022Article
- Protein Microarrays as a Tool to Analyze Antibody Responses to Variant Surface Antigens Expressed on the Surface of Plasmodium falciparum-Infected Erythrocytes.Methods in molecular biology (Clifton, N.J.) · 2022Article
- SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma.Microbiology spectrum · 2021Article
- Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination.NPJ vaccines · 2021Article
- Automated, flow-based chemiluminescence microarray immunoassay for the rapid multiplex detection of IgG antibodies to SARS-CoV-2 in human serum and plasma (CoVRapid CL-MIA).Analytical and bioanalytical chemistry · 2021Article
- Advances of nanomaterials-based strategies for fighting against COVID-19.View (Beijing, China) · 2021Review
- Predicting COVID-19 Severity with a Specific Nucleocapsid Antibody plus Disease Risk Factor Score.mSphere · 2021Article
Corrections and comments
- Update of
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
To detect the presence of antibodies in blood against SARS-CoV-2 in a highly sensitive and specific manner, here we describe a robust, inexpensive ($200), 3D-printable portable imaging platform (TinyArray imager) that can be deployed immediately in areas with minimal infrastructure to read coronavirus antigen microarrays (CoVAMs) that contain a panel of antigens from SARS-CoV-2, SARS-1, MERS, and other respiratory viruses. Application includes basic laboratories and makeshift field clinics where a few drops of blood from a finger prick could be rapidly tested in parallel for the presence of antibodies to SARS-CoV-2 with a test turnaround time of only 2-4 h. To evaluate our imaging device, we probed and imaged coronavirus microarrays with COVID-19-positive and negative sera and achieved a performance on par with a commercial microarray reader 100× more expensive than our imaging device. This work will enable large scale serosurveillance, which can play an important role in the months and years to come to implement efficient containment and mitigation measures, as well as help develop therapeutics and vaccines to treat and prevent the spread of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.